Since the outset of the COVID-19 pandemic, 10 to 30 per cent of the general population has experienced some form of virus-induced cognitive impairment, including trouble concentrating, brain fog or memory loss.
Pharmalittle: We’re reading about a Roche obesity drug, an experimental Lilly insulin, and more
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus again. Our spirits remain
May 16, 2024